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Abstract 
Stereodivergent syntheses leading to the different stereoisomers of a product are useful in the 
discovery and testing of drugs and agrochemicals. A longstanding challenging in catalysis, 
developing sets of stereodivergent catalysts is often solved for enzymes by screening Nature’s 
diversity for biocatalysts with complementary stereoselectivities. Here, Nature’s protein diversity 
has been leveraged to develop stereodivergent catalysts for a reaction not known in biology, 
cyclopropanation via carbene transfer. By screening diverse native and engineered heme 
proteins, we identified globins and serine-ligated cytochromes P450 with promiscuous activity 
for cyclopropanation of unactivated alkene substrates. Their activities and stereoselectivities 
were enhanced by directed evolution: 1-3 rounds of site-saturation mutagenesis and screening 
generated enzymes that catalyze the stereodivergent cyclopropanation to form each of the four 
stereoisomers of unactivated alkenes and electron-deficient alkenes with up to 5,400 total 
turnovers and 98% enantiomeric excess. These fully genetically encoded biocatalysts function 
in whole E. coli cells in mild, aqueous conditions and provide the first example of 
enantioselective, intermolecular iron-catalyzed cyclopropanation of unactivated alkenes via 
carbene transfer. 
 
 
 
  
Introduction 
The biological world is a marvelous ensemble of chiral molecules. From the amino acid and 
nucleoside building blocks that form proteins and DNA to intricate natural products produced by 
living organisms, chirality dictates how molecules interact with living systems.1 Many modern 
medicines draw inspiration from natural products.2 Because alternate stereoisomers can have 
very different biological effects,3 characterization of novel bioactive compounds during drug 
candidate screening should include testing each stereoisomer.4 Developing stereodivergent 
syntheses, where a set of complementary catalysts can generate every possible stereoisomer of 
the product, is therefore useful and is actively sought after in catalysis.5 Enzymes are green, 
sustainable options for stereoselective catalysis, and stereo-complementary enzymes can often 
be found in nature’s diversity: lipases6, ketoreductases7, and transaminases8 chosen using 
genome mining9, for example, have all afforded products with different stereoselectivities. We 
show here that natural protein diversity can be leveraged in a similar fashion to achieve 
stereodivergence for a new, non-natural enzyme-catalyzed reaction, cyclopropanation of 
unactivated alkenes. 
 
Previous work from this group and others has shown that iron-porphyrin (heme) proteins can be 
engineered to catalyze the cyclopropanation of styrenyl alkenes with ethyl diazoacetate (EDA, 
1).10-13 This new-to-nature carbene transfer reaction has been applied in the synthesis of key 
pharmaceutical intermediates such as levomilnacipran14, ticagrelor15-16, and tasimelteon.16 Thus 
far, however, alkene cyclopropanation by heme proteins with the native iron cofactor has been 
limited to styrenyl and other activated alkenes. Unactivated, aliphatic alkenes are attractive 
feedstocks for chemical synthesis, but their transformation to higher-value chiral products is 
challenging due to their inert nature, high degree of conformational flexibility, and limited steric 
and electronic bias to guide stereocontrol.17  
 
State-of-the art methods for unactivated alkene cyclopropanation often rely on noble metals18-20 
(Supplemental Table S1); no iron-based catalyst for the enantioselective intermolecular 
cyclopropanation of unactivated alkenes has been reported. However, directed evolution of heme 
proteins has previously enabled biocatalysis to access reactions performed with noble-metal 
catalysts, such as carbonsilicon bond formation21 and intermolecular CH amination22. We 
therefore set out to create a genetically encoded catalyst with the native heme cofactor that could 
cyclopropanate unactivated alkenes.  Furthermore, we wished to take advantage of the natural 
diversity of heme proteins to identify suitable starting points for engineering stereodivergent 
biocatalysts. 
 
Results and Discussion 
 
We collected a panel of eleven heme proteins from thermophilic and hyperthermophilic bacteria 
and archaea to test for unactivated alkene cyclopropanation (Supplemental Table S2). 
Thermostable proteins can better withstand the destabilizing effects of mutations and are 
therefore more ‘evolvable’.23 They are also often easier to work with and better tolerate polar 
organic solvents used to solubilize substrates. Wild-type Aeropyrum pernix protoglobin (ApePgb 
WT, UniProt ID: Q9YFF4) and wild-type Rhodothermus marinus nitric oxide dioxygenase 
(RmaNOD WT, UniProt ID: D0MGT2) were found to have low but measurable cyclopropanation 
activity on 1-octene 2a, catalyzing the reaction with 18 and 27 total turnovers per enzyme active 
site (TTN). Notably, ApePgb WT and RmaNOD WT displayed complementary 
diastereoselectivity, preferentially producing cis (1R, 2S)-3a and trans (1S, 2S)-3a, respectively.  
 
In addition to searching natural heme protein diversity for this novel reactivity, we also investigated 
heme proteins obtained in previous directed evolution studies. A panel of 36 variants of a Bacillus 
megaterium cytochrome P450 (BM3) engineered for other non-natural carbene and nitrene 
transfer reactions13 was tested for the ability to cyclopropanate 1-octene 2a and 4-phenyl-1-
butene 2b. 2b was chosen as a substrate for library screening, because the UV-visible phenyl 
group enables screening by HPLC-UV. BM3 variant P411-CIS L437F T438Q L75Y L181I (P411-
UA, sequence in Supporting Information) showed significant activity and selectivity for production 
of cis (1S, 2R)-3a, the third of the four possible isomers. This variant of a serine-ligated “P411” 
(P411-CIS24) had been engineered for cyclopropanation reactivity on electron-rich, non-styrenyl 
alkenes such as N-vinyl amides (Brandenberg et al., unpublished results).   
 
Site-saturation mutagenesis libraries were generated and screened to increase the activities and 
selectivities of the different enzymes. Because crystal structures of ApePgb and RmaNOD have 
not been reported, homology models were built to help us identify residues within the putative 
distal heme pocket, where carbenoid formation and substrate binding are predicted to take place 
(Supplemental Figure S2). P411-UA residues were selected based on the crystal structure of its 
P411-CIS predecessor (PDB ID: 4H23). Individual site-saturation libraries were screened for 
increased activity and diastereoselectivity using 4-phenyl-1-butene (2b) and EDA 1 as substrates. 
Variants with enhanced diastereoselectivity in the production of 3b were regrown in larger scale, 
and their activities were tested in cyclopropanation of 4-phenyl-1-butene (2b) and 1-octene (2a) 
with EDA. Enzyme variants with the greatest overall selectivity enhancements against 3a and 3b 
were used as parents in the next rounds of site-saturation mutagenesis and screening. A single 
mutation (Q52V) gave RmaNOD near-perfect stereoselectivity for producing trans (1S, 2S)-3a. 
Three mutations (W59A Y60G F145W, or “AGW”) gave ApePgb the ability to make cis (1R, 2S)-
3a with 89:11 diastereomeric ratio (d.r.) and 99% enantiomeric excess (e.e.). During screening to 
increase P411-UA’s cis diastereoselectivity, a single mutation, V87F, was found to completely 
invert the diastereoselectivity from 89:11 cis (1S, 2R)-3a to 4:96 trans (1R, 2R)-3a, affording the 
fourth and final stereoisomer we needed. Residue 87 is known to modulate the stereoselectivity 
of P450 BM3 for oxygenation of various substrates.25  
 
With initial screening of 11 new and 36 previously engineered proteins, followed by just one to 
three rounds of site-saturation mutagenesis, we discovered four protein variants capable of 
cyclopropanating unactivated alkenes (RmaNOD Q52V, ApePgb W59A Y60G F145W (= ApePgb 
AGW), P411-UA-V87C, and P411-UA-V87F), each of which produced a distinct stereoisomer of 
the desired product 3a with 89:11 to <1:99 d.r. and 96 to >99% e.e. (Figure 1). The enzyme 
activities against unactivated alkenes are comparable to the state-of-the-art catalysts, with 100-
490 TTN for 3a and as high as 2,400 TTN for 3b, the substrate against which the enzymes were 
screened. The system is straightforward and easy to use: the protein-expressing bacterial cells 
need only be resuspended to the desired concentration and the alkene and diazo ester added 
directly under an anaerobic atmosphere. When the reaction is complete, the product is extracted 
into organic solvents for analysis or purification. While these enzymes were optimized for use in 
whole cells, they also function to some degree in lysates and as purified proteins (Supporting 
Information). 
 
The four engineered biocatalysts were tested on a range of alkenes. Their activities and 
selectivities were high on unbranched aliphatic alkenes similar to those for which they were 
engineered, but their substrate scope extends to sterically hindered and electron-deficient alkenes 
as well (Figure 2). Though activity and stereoselectivity differed on different substrates, each 
catalyst accepted most of the substrates tested. It is likely that activity on specific substrates can 
be optimized further, if desired, as has been shown in many other directed evolution studies.26,27 
 
The small-molecule catalyzed enantioselective preparation of cyclopropyl esters from electron-
deficient alkenes has previously been limited to making the trans-cyclopropanes,28 whereas 
strategies to directly access 1-keto,2-ester or 1,2-diester cis-cyclopropanes (or their 
corresponding carboxylates) via enantioselective cyclopropanation are unknown. The 
biocatalysts, in contrast, enable access to the cis-1-keto,2-ester and cis-1,2-diester products in a 
single, intermolecular step using an E. coli–based platform ((1R, 2S)- and (1S, 2R)-3c, (1R, 2S)-
3g, Figure 2). Some of these products are precursors to valuable compounds: cyclopropyl esters 
of unbranched, aliphatic alkenes are used in fragrances, for example, including the essential 
odorants in frankincense.29 Notably, the enzymes catalyze the reaction on 2-vinylpyridine (2h), 
which is a difficult substrate for many catalysts due to pyridine’s propensity to coordinate to and 
inhibit metal centers. This cyclopropanation product is a precursor for an orphan GPR88 agonist.30 
 
Enzymes are chemoselective and can generate desired products without additional steps to 
protect and deprotect other reactive functional groups on the same molecule. As shown in Figure 
3, the enzymes described here, for example, can selectively cyclopropanate terminal alkenes in 
the presence of alcohol and carboxylic acid functional groups which often undergo competitive 
OH insertion reactions with small-molecule carbene transfer catalysts like rhodium acetate 
dimer.31 ApePgb AGW performed particularly well with unprotected 7-octen-1-ol (2i) and 7-octen-
1-oic acid (2j), yielding products (1R, 2S)-3i and (1R, 2S)-3j at 77% and 64% isolated yield, 
respectively, in preparative-scale reactions. Some functional groups cannot be protected easily, 
and chemo- and regioselectivity is even more important in these cases. In the cases of 1,3-(E)-
pentadiene (2k) and 1,3-(Z)-pentadiene (2l), all four engineered proteins cyclopropanate the 
terminal alkene with perfect regioselectivity, likely due to the steric constraints in each enzyme’s 
active site that direct catalysis to the more accessible double bond. The diastereoselectivity varied 
for 3k and 3l, though the enantioselectivity for the major isomer remained high. As the electronic 
properties of 2k and 2l are similar, the difference in stereoselectivity likely reflects steric 
constraints of the enzyme active sites. 
 
Citing the need for a greater reactivity of the metal center to cyclopropanate unactivated alkenes, 
Hartwig, Clark, and coworkers showed that heme proteins could bind an artificial iridium cofactor 
in place of iron heme and perform carbene transfer chemistry.19 They showed that a protein’s 
active site can confer selectivity to noble-metal, small-molecule catalysts that can already catalyze 
the reaction.19,20,32 Use of an artificial iridium cofactor (Ir(Me)PIX) required the lysis, purification, 
and in vitro metalation of the apoprotein with the Ir(Me)PIX, all of which add time and cost to 
catalyst preparation. Though it may be possible to perform these metalations in vivo,33 the 
synthetic, noble-metal catalyst is far more expensive than the native heme cofactor, which is 
manufactured by the cell and loaded into the catalyst during protein expression in vivo. The use 
of iridium is also not ideal due to the negative impact mining and refining precious metals has on 
the environment.34  
 
A noble-metal catalyst is not necessary, however, for these reactions. Two decades ago, Woo 
and coworkers showed that iron meso-tetrakis(pentafluorophenyl)porphyrin chloride (Fe(PFP)Cl) 
can catalyze the reaction of 2-ethyl-1-butene and EDA with 390 TTN; they reported the formation 
of cyclopropane products using 1-decene as well.35 In fact, we observed that iron heme in 
aqueous buffer, with no protein, can catalyze the formation of 3a, albeit with only 0.4 TTN. This 
basal activity is greatly enhanced and stereoselectivity is enforced by the protein environment, 
allowing the heme proteins described here to cyclopropanate a range of alkenes from electron-
rich conjugated dienes to electron-deficient vinyl ketones and acrylates with high diastereo- and 
enantioselectivity. The primary factor in determining activity appears to be the binding of the 
alkene in a productive configuration: the heme’s local protein environment can be molded to 
enhance activity and selectivity by optimizing the substrate binding modes. Different local heme 
environments can be accessed by screening natural and engineered protein diversity. Directed 
evolution then fine-tunes these features. 
 
Metalloporphyrin catalysts have been used in synthetic chemistry for decades, but nature has 
used them for millions of years. Present in all forms of life on Earth, heme-binding proteins have 
diverse functions as well as promiscuous activities for which they were never selected, such as 
the ability to form reactive carbene intermediates. We have taken advantage of this natural 
diversity to find catalysts for reactions not known to be catalyzed in biology, but that are 
synthetically useful and are driven by a synthetic carbene precursor (EDA).  
 
While biocatalysts often possess very high selectivity, this selectivity can be synthetically limiting. 
A single enzyme may make only a single isomer, but access to other isomers may be equally 
important. Natural diversity can be leveraged effectively for this challenge. A combination of 
natural diversity and directed evolution let us realize the stereodivergent cyclopropanation of 
unactivated and electron-deficient alkenes in mild, aqueous conditions with a fully genetically 
encoded heme protein expressed in bacteria. This set of biocatalysts can serve as starting points 
for green, sustainable synthesis of valuable cyclopropanated products.  
 
Supporting Information 
The materials and experimental methods, detailed protein engineering strategies for each variant, 
and compound characterization are available in the Supporting Information. 
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 Figure 1. Stereoselective enzymatic cyclopropanation of the aliphatic alkene 1-octene 2a and 
EDA 1 to obtain each of four stereoisomers of cyclopropane product 3a with diastereoselectivies 
from 89:11 to <99:1 d.r. and enantioselectivies from 96% to >99% e.e.. Reaction conditions: whole 
E. coli cells in M9-N buffer, 25 mM glucose, 10 mM 1-octene 2a, direct addition of 20 mM EDA 1 
under anaerobic conditions, 5% ethanol cosolvent. Catalysts used: rhodium acetate dimer 
(Rh2(OAc)4) to form the racemic authentic standard, two variants of the engineered, serine-ligated 
cytochrome P450-BM3 (P411-UA V87C and P411-UA V87F), Aeropyrum pernix protoglobin 
W59A Y60G F145W (ApePgb AGW), and Rhodothermus marinus nitric oxide dioxygenase Q52V 
(RmaNOD Q52V). Protein sequences are available in the Supporting Information.  
  
Figure 2. Cyclopropanation substrate scope. a) Activity and selectivity of each protein variant 
against 3a, 3b, and 3c. b) Activity and selectivity against a variety of alkenes. Activity and 
selectivity reported for single enzymes denoted by superscripts: 1: Ape AGW, 2: RmaNOD Q52V. 
Reaction conditions: whole E. coli cells (OD600 = 5 (ApePgb AGW, RmaNOD Q52V), OD600 = 20 
(P411-UA V87C, P411-UA V87F) in M9-N buffer, 25 mM glucose, 10 mM 1-octene 2a, direct 
addition of 20 mM EDA 1 under anaerobic conditions, 5% ethanol cosolvent. Chiral separation 
conditions reported in the Supporting Information. *: The benzyl ester of 3c has IUPAC naming 
priority and therefore the chiral carbon numbering is reversed for these compounds.   
 
Figure 3. Preparative-scale syntheses of unactivated alkene cyclopropanation products. 
Preparative-scale reactions against substrates with free alcohol (7-octen-1-ol, 2i), free carboxylic 
acid (7-octen-1-oic acid, 2j), the two diastereomers of 1,3-pentadiene 2k and 2l, and ketone (5-
hexen-2-one, 2m). Activity and selectivity reported for single enzymes denoted by superscripts:1: 
ApePgb AGW, 2: RmaNOD Q52V. Reaction and separation conditions are available in the 
Supporting Information. 
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